Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simethicone Addition to PEG for Bowel Preparation in CRC Screening
NCT03816774Completed
- Sponsor
- IPO Coimbra
- Start
- Jun 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of simethicone in colorectal cancer (CRC) (2 arms), sponsored by IPO Coimbra. Primary endpoint: Adequate bowel preparation rate at 1 day. Started Jun 2019; status: completed.
02
Drugs
simethicone
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03816774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816774.